This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 10/20/2026
Antozzi et al (2025)1,2 evaluated the efficacy and safety of IMAAVY in adults with gMG in a phase 3, randomized, multicenter, DB, PBO-controlled study.

Abbreviations: AchR+, acetylcholine receptor positive; COVID-19,coronavirus disease 2019; EU, European Union; IV, intravenous; LD, loading dose; MG-ADL, Myasthenia Gravis-Activities of Daily Living; MGFA,Myasthenia Gravis Foundation of America; MuSK+, muscle-specific tyrosine kinase ositive; OLE, open-label extension; Q2W, every 2 weeks; R, randomized; SOC, standard-of-care; US, United States; W, week.
a
b
c
d
e
| IMAAVY → IMAAVY + SOC | PBO → IMAAVY + SOC | |
|---|---|---|
| Analysis set: seropositive efficacya, n | 71 | 66 |
| Mean age, years (range) | 51.1 (20-81) | 51.6 (20-81) |
| Female, n (%) | 46 (64.8) | 38 (57.6) |
| Baseline MG-ADL total score, mean (SD) | 9.3 (2.75) | 9.0 (1.98) |
| Baseline QMG total score, mean (SD) | 15.2 (4.85)b | 15.6 (4.90) |
| Anti-AChR+/anti-MuSK+/anti-LRP4+, n | 59/10/2 | 61/4/1 |
| Abbreviations: AChR, acetylcholine receptor; DB, double-blind; LRP4, low-density lipoprotein receptor-related protein 4; MG-ADL, Myasthenia Gravis Activities of Daily Living; MuSK, muscle-specific tyrosine kinase; OLE, open-label extension; PBO, placebo; QMG, Quantitative Myasthenia Gravis; SD, standard deviation; SOC, standard of care. aAll randomized seropositive patients who received ≥1 dose of study intervention in the DB phase or all seropositive patients who received ≥1 dose of IMAAVY in the OLE phase. bn=67 | ||

Abbreviations: DB, double-blind; MG-ADL, Myasthenia Gravis Activities of Daily Living; Nipo, nipocalimab; OL, open-label; OLE, open-label extension; PBO, placebo; SE, standard error; W, week.

Abbreviations: DB, double-blind; OL, open-label; Nipo, nipocalimab; OLE, open-label extension; PBO, placebo; QMG, Quantitative Myasthenia Gravis; SE, standard error; W, week.
| OLE All IMAAVY | |||
|---|---|---|---|
| Analysis set, n | 176 | ||
| Average follow-up duration, weeks | 70.53 | ||
| PYa | 237.9 | ||
| Events/PY | Events, n | Patients, nb | |
| All AEs | 5.59 | 1331 | 159 |
| Serious AEs | 0.31 | 74 | 46 |
| Fatal AEs | 0.02 | 4 | 4 |
| Treatment discontinuation due to AEsc | 0.05 | 13 | 13 |
| Infections and infestations | 1.39 | 330 | 125 |
| Infusion-related reactionsd | 0.07 | 17 | 10 |
| Adjudicated MACE, fatal | 0.01 | 3 | 3 |
| Adjudicated MACE, not fatal | 0.03 | 7 | 1 |
| Abbreviations: AE, adverse event; DB, double-blind; eCRF, electronic case report form; MACE, major adverse cardiac events; OLE, open-label extension; PY, patient years. aPY of observation is calculated as the total duration of follow-up in days/365.25. bPatients with ≥1 AE are shown. cPermanent discontinuation of treatment. Treatment discontinuation for an AE with onset in the DB (or OLE) phase occurred in the DB (or OLE) phase. dIndicated as infusion reaction by investigator on eCRF and relationship to study intervention= “Related”. | |||
| OLE All IMAAVY (n=176) | |||
|---|---|---|---|
| PYa | 237.9 | ||
| Events/PYa | Events, n | Patients, nb | |
| Upper respiratory tract infection | 0.21 | 50 | 39 |
| Nasopharyngitis | 0.18 | 44 | 33 |
| COVID-19 | 0.11 | 25 | 23 |
| Urinary tract infection | 0.12 | 28 | 19 |
| Back pain | 0.09 | 22 | 18 |
| Muscle spasms | 0.08 | 19 | 12 |
| Pain in extremity | 0.05 | 11 | 10 |
| Arthralgia | 0.08 | 18 | 13 |
| Myasthenia gravis | 0.20 | 48 | 31 |
| Headache | 0.21 | 50 | 29 |
| Dizziness | 0.02 | 5 | 4 |
| Peripheral edema | 0.04 | 10 | 9 |
| Pyrexia | 0.05 | 11 | 10 |
| Diarrhea | 0.08 | 20 | 20 |
| Nausea | 0.04 | 10 | 8 |
| Cough | 0.04 | 10 | 9 |
| Rash | 0.02 | 5 | 4 |
| Anemia | 0.03 | 7 | 7 |
| Insomnia | 0.02 | 4 | 4 |
| Abbreviations: AE, adverse event; COVID-19, coronavirus disease 2019; OLE, open-label extension; PY, patient years. aPY of observation is calculated as the total duration of follow-up in days/365.25. bPatients with ≥1 AE are shown. AEs listed where system organ class event rate (number of events/PY) is ≥0.1 or preferred term event rate (number of events/PY) is ≥0 in either treatment group. | |||

Abbreviations: DB, double-blind; IgG, immunoglobulin G; Nipo, nipocalimab; OL, open-label; OLE, open-label extension; PBO, placebo; SE, standard error; W, week.
A literature search of MEDLINE®
| 1 | Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. |
| 2 | |
| 3 | |
| 4 | |
| 5 |
Would you like to clear and leave your conversation? Message history will be lost.